Homepage - GRAIL GRAIL is a healthcare company innovating to solve healthcare’s most important challenges Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable
Multi-cancer early detection - GRAIL GRAIL uses advanced machine learning algorithms and pattern recognition to “read” methylation patterns Using these two principles, the Galleri test has three scientific steps: Extract and sequence the DNA fragments from the blood to “read” the methylation patterns (assay)
Press Releases - GRAIL GRAIL Presents New Data Demonstrating That Methylation Assay Detects Residual Hematologic Cancer After Treatment at American Association for Cancer Research Annual Meeting 2023
Clinical Studies - GRAIL GRAIL Updates; The Cancer SIGNAL Podcast; Media Resources; Investor Relations; Galleri Test; Careers; Get in touch; Search Our clinical study program We are committed to the utmost scientific rigor and have enrolled over 300,000 participants in a clinical study program to demonstrate broad applicability of our multi-cancer early detection
Careers - GRAIL Everything we do is guided by our mission to detect cancer early, when it can be cured We have a group of people at GRAIL whose talent, commitment, and creativity are unmatched And as we grow, we’re looking for people who will increase the impact we can make on the world
Diagnostic Aid for Cancer - GRAIL GRAIL Updates; The Cancer SIGNAL Podcast; Media Resources; Investor Relations; Galleri Test; Careers; Get in touch; Search Diagnostic Aid for Cancer We are developing our diagnostic aid for cancer (“DAC”) test to accelerate diagnostic resolution for patients with non-specific signs and symptoms, but with a clinical suspicion of cancer
GRAIL and Quest Diagnostics Provide GRAIL’s Galleri® Multi-Cancer Early . . . GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring
GRAIL Advances the Galleri® Registrational Clinical Trial Program GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring
Leadership Team - GRAIL To pursue a mission like GRAIL’s, it takes all of us—a unified collective of courageous, adaptable, and open-minded big thinkers dedicated to creating a better world Our leadership team strives to push the boundaries of what is possible to achieve our bold mission
GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results MENLO PARK, Calif , Feb 20, 2025 PRNewswire -- GRAIL, Inc (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business updates